The Technical Analyst
Capricor Therapeutics Inc [CAPR]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Capricor Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
2.18% $5.15
America/New_York / 25 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 162.24 mill |
| EPS: | -0.830 |
| P/E: | -6.20 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 31.50 mill |
| Avg Daily Volume: | 0.306 mill |
| RATING 2024-04-25 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | |||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -6.20 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.05x |
| Company: PE -6.20 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 4.70 - 5.61 ( +/- 8.83%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-23 | Collier Earl M Jr | Buy | 30 000 | Common Stock |
| 2024-04-23 | Collier Earl M Jr | Sell | 30 000 | Stock Option (Right to Buy) |
| 2024-04-23 | Musket David B | Buy | 16 156 | Common Stock |
| 2024-04-23 | Musket David B | Sell | 5 750 | Stock Option (Right to Buy) |
| 2024-01-02 | Kelliher Mike | Buy | 30 000 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 78.98 |
| Last 97 transactions |
| Buy: 2 824 525 | Sell: 392 146 |
Forecast:
16:00 - $5.12
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $5.12
Forecast 2: 16:00 - $5.12
Forecast 3: 16:00 - $5.12
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $5.15 (2.18% ) |
| Volume | 0.388 mill |
| Avg. Vol. | 0.306 mill |
| % of Avg. Vol | 126.63 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CAPR
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
CAPR
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
Latest Press Releases
2024-04-24 09:00:00 - Press Release
Capricor Therapeutics Announces Positive Type-b Meeting With Fda For Cap-1002 Program For Duchenne Muscular Dystrophy
-company aligned with fda on demonstration of non-clinical comparability; allowing for immediate use of san diego manufacturing facility-
2024-03-21 08:30:00 - Press Release
Capricor Therapeutics To Present At Upcoming Investor Conferences
San diego, march 21, 2024 (globe newswire) -- capricor therapeutics (nasdaq: capr), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, today announced that the company is scheduled to present at two upcoming investor conferences.
2024-03-06 08:30:00 - Press Release
Capricor Therapeutics Presents At 2024 Muscular Dystrophy Association (mda) Clinical & Scientific Conference
Presentation highlights positive 24-month results from hope-2 open label extension study of cap-1002 in duchenne muscular dystrophy presentation highlights positive 24-month results from hope-2 open label extension study of cap-1002 in duchenne muscular dystrophy
2024-02-29 16:05:00 - Press Release
Capricor Therapeutics Reports Fourth Quarter And Full Year 2023 Financial Results And Provides Corporate Update
-enrollment complete in cohort a of phase 3, pivotal, hope-3 trial of cap-1002 in duchenne muscular dystrophy; announced successful interim futility analysis; on track to report top-line data in q4 2024-
2024-02-27 08:30:00 - Press Release
Capricor Therapeutics Announces Upcoming Type-b Meeting With The Fda To Discuss Commercial Manufacturing Planning With An Aim To Expedite Bla Pathway For Cap-1002 In Duchenne Muscular Dystrophy
San diego, feb. 27, 2024 (globe newswire) -- – capricor therapeutics (nasdaq: capr), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, announced today that the company has been granted an in-person type-b meeting with the u.s. food & drug administration (fda) scheduled for late march. in the upcoming meeting with the fda, the company intends to discuss its proposed chemistry, manufacturing and controls (cmc) plans for commercial launch, if approved which may enable opportunities to expedite the pathway to a biologics license application (bla) submission. the company has previously been granted regenerative medicine advanced therapy (rmat) and orphan drug designations for the use of cap-1002 in duchenne muscular dystrophy (dmd) and these designations enable sponsors to work closely with the fda and receive its guidance on potential expedited pathways for approval.
Latest News
2024-04-10 10:56:06 - Zacks Investment Research
Wall Street Analysts Predict a 218.18% Upside in Capricor (CAPR): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 218.2% in Capricor (CAPR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
2024-03-25 10:56:10 - Zacks Investment Research
How Much Upside is Left in Capricor (CAPR)? Wall Street Analysts Think 229.15%
The mean of analysts' price targets for Capricor (CAPR) points to a 229.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
2024-03-21 08:30:00 - GlobeNewsWire
Capricor Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, today announced that the Company is scheduled to present at two upcoming investor conferences.
2024-03-07 10:56:07 - Zacks Investment Research
Can Capricor (CAPR) Climb 261.27% to Reach the Level Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 261.3% in Capricor (CAPR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
2024-02-22 08:30:00 - GlobeNewsWire
Capricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29
SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, will release its financial results for the fourth quarter and full year ended December 31, 2023, after the market close on Thursday, February 29, 2024. Management will then host a webcast and conference call at 4:30 p.m.
2023-11-14 20:30:05 - Seeking Alpha
Capricor Therapeutics, Inc. (CAPR) Q3 2023 Earnings Call Transcript
Capricor Therapeutics, Inc. (NASDAQ:CAPR ) Q3 2023 Results Conference Call November 14, 2023 4:30 PM ET Company Participants AJ Bergmann - CFO Linda Marbán - CEO Conference Call Participants Joe Pantginis - H.C. Wainwright Aydin Huseynov - Ladenburg Operator Good afternoon, ladies and gentlemen and welcome to the Capricor's Third Quarter 2023 Financial Results and Corporate Update Call.
2023-11-07 09:15:00 - GlobeNewsWire
Capricor Therapeutics to Present Third Quarter 2023 Financial Results and Recent Corporate Update on November 14
SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, will release its financial results for the third quarter ended September 30, 2023, after the market close on Tuesday, November 14, 2023. Management will then host a webcast and conference call at 4:30 p.m.
2023-10-25 11:22:35 - Zacks Investment Research
After Plunging -52.01% in 4 Weeks, Here's Why the Trend Might Reverse for Capricor (CAPR)
Capricor (CAPR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
2023-10-24 11:18:36 - Zacks Investment Research
After Plunging -50.99% in 4 Weeks, Here's Why the Trend Might Reverse for Capricor (CAPR)
The heavy selling pressure might have exhausted for Capricor (CAPR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
2023-08-07 18:42:07 - Seeking Alpha
Capricor Therapeutics, Inc. (CAPR) Q2 2023 Earnings Call Transcript
Capricor Therapeutics, Inc. (NASDAQ:CAPR ) Q2 2023 Earnings Call Transcript August 7, 2023 4:20 PM ET Company Participants AJ Bergmann - CFO Linda Marban - CEO Conference Call Participants Joe Pantginis - H.C. Wainwright Operator Good afternoon, ladies and gentlemen and welcome to the Capricor Therapeutics Second Quarter 2023 Financial Results and Corporate Update Call.